Your browser doesn't support javascript.
loading
Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials.
Linden, Katie; McQuillan, Conor; Brennan, Paul; Menown, Ian B A.
Affiliation
  • Linden K; Craigavon Cardiac Centre, SHSCT, Craigavon, Northern Ireland, UK. kmslinden@gmail.com.
  • McQuillan C; Craigavon Cardiac Centre, SHSCT, Craigavon, Northern Ireland, UK.
  • Brennan P; Craigavon Cardiac Centre, SHSCT, Craigavon, Northern Ireland, UK.
  • Menown IBA; Craigavon Cardiac Centre, SHSCT, Craigavon, Northern Ireland, UK.
Adv Ther ; 36(7): 1549-1573, 2019 07.
Article in En | MEDLINE | ID: mdl-31065993
ABSTRACT

INTRODUCTION:

Many important clinical trials in cardiology were published or presented at major international meetings throughout 2018. This paper aims to offer a concise overview of these significant advances and to put them into clinical context.

METHODS:

Trials presented at the major international cardiology meetings during 2018 were reviewed including The American College of Cardiology, EuroPCR, The European Society of Cardiology, PCR London Valves, Transcatheter Cardiovascular Therapeutics, and the American Heart Association. In addition to this a literature search identified several other publications eligible for inclusion based on their relevance to clinical cardiology, their potential impact on clinical practice and on future guidelines.

RESULTS:

A total of 78 trials met the inclusion criteria. New interventional and structural data include trials examining novel stent designs (Biofreedom™, COMBO), use of drug-coated balloons in patients with high bleeding risk, intervention in stable coronary artery disease, revascularisation strategy in ST elevation myocardial infarction, transcatheter aortic valve replacement in low-risk patients, and percutaneous mitral or tricuspid valve interventions. Preventative cardiology data included the use of sodium glucose cotransporter-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin), proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (alirocumab) and approaches of hypertension management. Antiplatelet data included trials evaluating both the optimal length of course and combination of antiplatelet agents. Heart failure data included trials of sacubitril-valsartan during acute hospital admission and the management of chemotherapy-induced cardiotoxicity. Electrophysiology data included trials examining atrial fibrillation ablation, wearable cardiac defibrillators (LifeVest) and His-bundle pacing.

CONCLUSION:

This article presents key clinical trials completed during 2018 and should be valuable to both cardiology clinicians and researchers.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Patient Care Management / Cardiology / Heart Diseases Type of study: Diagnostic_studies / Guideline / Prognostic_studies Limits: Humans Language: En Journal: Adv Ther Journal subject: TERAPEUTICA Year: 2019 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Patient Care Management / Cardiology / Heart Diseases Type of study: Diagnostic_studies / Guideline / Prognostic_studies Limits: Humans Language: En Journal: Adv Ther Journal subject: TERAPEUTICA Year: 2019 Document type: Article Affiliation country:
...